InvestorsHub Logo
Followers 5
Posts 859
Boards Moderated 0
Alias Born 09/28/2012

Re: Fred Kadiddlehopper post# 5387

Thursday, 12/07/2017 10:51:19 AM

Thursday, December 07, 2017 10:51:19 AM

Post# of 8553
Fewer targets but slightly better terms than the Bmy's deal. Not bad. I have no idea why Roche paid $30M for just one target but they must've had good reasons.

One more deal should take us to $25:

"Dr. Helen Torley, president and CEO of Halozyme. “ENHANZE has become the industry standard for converting intravenous therapies to a subcutaneous delivery,..."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News